Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 36Unknown 23Recruiting 23Not yet recruiting 13Withdrawn 8Active not recruiting 6Terminated 3Enrolling by invitation 1

Sponsor Class

NIH 4INDUSTRY 4OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2Thoracic 1Other hematologic neoplasm 1

Conditions

Breast Neoplasms 723Neoplasms 461Prostatic Neoplasms 398Carcinoma, Non-Small-Cell Lung 388Lung Neoplasms 311Leukemia, Myeloid, Acute 301Multiple Myeloma 270Colorectal Neoplasms 243Neoplasm Metastasis 240Pancreatic Neoplasms 238Leukemia 235Melanoma 217Lymphoma 213Precursor Cell Lymphoblastic Leukemia-Lymphoma 204Brain Neoplasms 195Recurrence 178Head and Neck Neoplasms 177Lymphoma, Non-Hodgkin 174Myelodysplastic Syndromes 168Leukemia, Lymphocytic, Chronic, B-Cell 168Ovarian Neoplasms 160Carcinoma, Hepatocellular 154Glioblastoma 149Carcinoma, Renal Cell 137Rectal Neoplasms 134Colonic Neoplasms 129Lymphoma, Large B-Cell, Diffuse 125Lymphoma, Follicular 125Hodgkin Disease 116Squamous Cell Carcinoma of Head and Neck 109

Interventions

umbralisib 1ublituximab 1fludarabine phosphate 1fludarabine 1brigatinib 1binimetinib 1axicabtagene ciloleucel 1Receptors, Interleukin-6 1Interleukin 1 Receptor Antagonist Protein 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × OTHER × Disease Progression × Clear all
NCT04205838 2026-02-27

Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma

Jonsson Comprehensive Cancer Center

Phase 2 Terminated
23 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Disease Progression

NCT04149821 2023-06-15

Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy

Weill Medical College of Cornell University

Phase 2 Terminated
1 enrolled 8 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Disease Progression

NCT04005144 2022-10-17

Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer

University of California, San Francisco

Phase 1 Terminated
3 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡